Strongbridge Biopharma plc (NASDAQ: SBBP) is a biopharmaceutical company focused on rare endocrine disorders and other rare diseases. The company is committed to the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises. Its primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. For more information, visit the company’s website at www.strongbridgebio.com.